Consolidated financial statements

The financial statements of dsm-firmenich include the consolidated financial statements and the parent company financial statements. dsm-firmenich (the ‘Company’ or the ‘Group’) is a new company following the merger between DSM and Firmenich on 8 May 2023. The merger has brought together one of the largest innovation and creation communities in nutrition, health, and beauty. With 30,000 employees and capabilities built on more than a century of pioneering science activities, dsm-firmenich has been established to play a leading role in the reinvention, manufacturing, and combination of vital nutrients, flavors, and fragrances.

The merger was effective on 8 May 2023 through an exchange offer by the Company to the DSM shareholders for all DSM ordinary shares and the contribution of all Firmenich Shares to the Company against issuance of DSM-Firmenich ordinary shares representing 34.5% of the total issued share capital of the Company and payment of an amount in cash of €3.5 billion.

The parent company of the Group, DSM-Firmenich AG, is domiciled in Kaiseraugst (Switzerland) and listed on the Euronext Amsterdam stock exchange. These consolidated financial statements comprise DSM-Firmenich AG and its subsidiaries (the ‘Group’). The consolidated financial statements are prepared in accordance with IFRS, which includes Firmenich from the merger date onwards. See also Note 1 General Information.

A list of main participations of the Group can be found in Note 3 Investments to the Parent company financial statements. The financial year 2023 covers the period from 1 January 2023 to 31 December 2023. The Board of Directors of DSM-Firmenich AG approved these consolidated financial statements for issue on 28 February 2024. They are subject to the approval by the Annual General Meeting on 7 May 2024.

Topic filter